ALLR$1.07+8.93%
Allarity Therapeutics, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$16.97M
Float & O/S:
Inst Own:
DilutionScan read 44 of Allarity Therapeutics, Inc.'s SEC filings and found 2 warrant series, 1 convertible, 1 ATM program, 1 equity line, 6 shelf registrations, 3 S-1 registrations and 3 completed offerings on file for ALLR. The latest dilution event on file is a registration statement on Apr 24, 2026. Analysis updated Nov 2, 2026.
Signal8 Summary
ALLR
Clinical-stage biotech with massive dilution
Snapshot
Allarity is a clinical-stage biotech focused on cancer treatments. It is a tiny micro-cap with negligible revenue of $320K in FY 2025 and a net loss of $11.2M. The business burns about $15M a year to fund operations.
What's Happening Right Now
- : The company secured $20 million in promissory note financing and a $6 million equity line, extending its cash runway into mid-2028.
- : Allarity began a Phase 3 manufacturing campaign for stenoparib, aiming to complete it by Q3 2026 to support a pivotal trial in advanced ovarian cancer.
- : Allarity received a Notice of Allowance from the USPTO for a patent covering its stenoparib companion diagnostic, potentially securing exclusivity into 2039.
